JPS59214767A - Kit for measuring specific protein in human pregnancy - Google Patents

Kit for measuring specific protein in human pregnancy

Info

Publication number
JPS59214767A
JPS59214767A JP8947783A JP8947783A JPS59214767A JP S59214767 A JPS59214767 A JP S59214767A JP 8947783 A JP8947783 A JP 8947783A JP 8947783 A JP8947783 A JP 8947783A JP S59214767 A JPS59214767 A JP S59214767A
Authority
JP
Japan
Prior art keywords
human
labeled
antibody
vessel
buffer liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8947783A
Other languages
Japanese (ja)
Inventor
Hiroyuki Watabe
博之 渡部
Tsunekazu Fukushima
恒和 福島
Satoru Funakoshi
船越 哲
Tadakazu Suyama
須山 忠和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan filed Critical Green Cross Corp Japan
Priority to JP8947783A priority Critical patent/JPS59214767A/en
Publication of JPS59214767A publication Critical patent/JPS59214767A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PURPOSE:To determine SP1 in a number of sample liquids quickly and accurately by a radio immunoassay by arranging an anti-human SP1 (pregnancy specific protein) antibody immobilizing vessel, a radioactive substance labeled human SP1 labeled human SP1 and a buffer liquid. CONSTITUTION:Labeled human SP1 is dissolved into a buffer liquid to prepare a standard calibration curve. Radioactive substance labeled human SP1 is preferably <125>I or <135>I labeled one and the labeling of human SP1 is done by the chloroamine T method or the like. A vessel is preferably a test tube-shaped on male of a synthetic resin. Anti-human SP1 antibody is obtained by emulsifying human SP1 with Freund's Adjuvant and sensitizing the emulsion to an animal such as rabbit and guinea pig. The anti-human SP1 antibody is diluted in the buffer liquid and after it is allowed to stand in the vessel, the dilusion liquid is removed. Then, the product is washed and dried to obtained anti-human SP1 antibody immobilization vessel. The radioactive substance-labeled SP1 and a buffer liquid are added to the vessel and after allowed to stand, it is washed to make an antibody immobilization vessel in which about 40-60% of the labeled SP1 is bonded. The buffer liquid herein used is, for example, a 0.1M phosphate- buffered physiological salt solution with pH7.

Description

【発明の詳細な説明】 不発肋Ji−1:、多数の被検液中の妊娠特異蛋白(S
P、)全ラジオイムノアッセイによって迅速かつ正?7
1 K定量することが可1セなヒ) SP、測定用キッ
トに関する。
[Detailed description of the invention] Unexploded rib Ji-1: Pregnancy-specific protein (S
P,) Rapid and positive by total radioimmunoassay? 7
1) SP, related to a measurement kit that is capable of quantifying K.

5PIVJ:、、妊婦血清中に特異的に出現する糖蛋白
として、1971年西ドイツベーリ/グウエルグ(ヘキ
スト社)のボーア(1(、Bohn )が発見した(A
rch、 GynMk、 、210.440 、197
1 )ものであり、その血清濃度が胎盤機能や胎児発育
の指標になり得るとして注目されている。
(A
rch, GynMk, , 210.440, 197
1), and its serum concentration is attracting attention as an indicator of placental function and fetal growth.

本発明の目的は多数の被検体について迅速かつ正61″
FにSPiを測定しりる瓶詰を提供することである。
The purpose of the present invention is to quickly and accurately test a large number of subjects.
The purpose is to provide bottlings that measure SPi to F.

木売り]は、抗ヒトsi’、抗体向定容略、放射性物J
l標識ヒトSP+1標牛ヒ)SP、及び緩衝液よりなる
ヒトSPI定tit用キットに門する。
Wood seller] is anti-human si', antibody specific volume, radioactive material J
A human SPI titration kit consisting of 1-labeled human SP, 1-labeled cow/hig) SP, and a buffer solution is included.

不発りjに関する標串ヒ)SP、は、後述1−る標ノ4
へ検量線を作成するために用いられるものであり、通融
汀ヒトSP1の(未結乾燥品よりなるものである。
SP, which is related to unexploded j, is 1-4, which will be described later.
It is used to create a calibration curve and is made from an undried product of Touyu Seihito SP1.

かかる標準ヒトSPIは、たとえi−j:参考例記戦の
方法によってえられ乙。標準ヒh si’+は緩画欣に
溶方Yして(吏用され、この1余たとえは1〜100n
f/meとなるように4〜5濃度段階まで小分けして標
L1(検量線の作成に1史用されろ。
Such a standard human SPI can be obtained by the method described in ii-j. The standard h si'+ is used as a melody Y (used in a loose drawing), and this one extra analogy is 1 to 100n.
Divide into 4 to 5 concentration levels so that f/me is used as standard L1 (used once to create a calibration curve).

放射性物質標識ヒ)SP、としては、たとえは、IZI
 、 +351標識したものか好ましいものとしてあけ
られ、ヒト尿5P11μ2当り、たとえば+251−C
−あれば105〜lO’cpm程度の比放射活性が2@
当である。放射性物質標識ヒトSP、?i、ヒ)SP、
を自体既知の方法、たとえばタロラミン1゛法(文献l
参照)、ラクトペルオキシダーゼ法(文献2参照)、ポ
ルトン−ノツター試薬法(又献3参照)にて標識するこ
とによって作成することができ乙。
Radioactive substance labeling (SP), for example, IZI
, +351-labeled or preferred, per human urine 5P11μ2, e.g. +251-C
- If the specific radioactivity is around 105~1O'cpm 2@
That's true. Radioactive substance labeled human SP? i, h) SP,
using methods known per se, such as the talolamine 1 method (Reference 1).
), the lactoperoxidase method (see Reference 2), and the Porton-Notter reagent method (see Reference 3).

抗ヒトsP、抗体固定谷器における容器は試験管状のも
のが好ましく、それは好ましくは直径5〜151111
11、長さ50〜loo間程度である。またその材質は
ポリスチレン、ボリグロビレン、ポリエチレンなどの合
成樹脂、カラスなとか適当であり、収り扱い易く、コス
トが低い点から合成朗脂製のものが好ましい。
The container in the anti-human sP, antibody immobilization device is preferably a test tube-like container, which preferably has a diameter of 5 to 151,111 mm.
11. The length is approximately between 50 and loo. The material may be synthetic resin such as polystyrene, polyglopylene, polyethylene, or glass, and synthetic resin is preferred because it is easy to store and handle and is inexpensive.

当該容器に固定するためのわLヒl−SPl抗体に、た
とえばヒトSP、iフロイドのアジュノ(ントと乳化し
たのち、ウサギ、モルモット、ラット、ヤギなどの動物
に感作させて得られる。ここで抗皿浦からの抗ヒ)SP
+抗体のRa製は、硫酸アンモニウウ沈澱法、イオン叉
換クロマトグラフィー、分子篩などの処理を単独または
組合せることによって行われる。
It can be obtained by emulsifying, for example, human SP or iFloyd adjuvant to the human SP1 antibody to be immobilized on the container, and then sensitizing the animal such as a rabbit, guinea pig, rat, or goat. anti-hito from anti-saraura) SP
+Ra production of antibodies is carried out by treatments such as ammonium sulfate precipitation, ion exchange chromatography, molecular sieves, etc., either alone or in combination.

抗ヒ)SP+抗体を容器に固定する方法としてはたとえ
ば次の如き方法があげられる。抗ヒトsp。
Examples of methods for immobilizing the anti-Human SP+ antibody on a container include the following methods. Anti-human sp.

抗体を、たとえば100倍、400倍、1600倍、6
400倍、25600倍、102400倍、40960
0倍程度に希釈する。ここで緩衝液としては、酢酸塩、
リン酸塩、トリス−塩酸塩などが利用できるか、特にO
,OIM酢酸ナトリウム緩術緩衝液i45.5 が好ま
しい。当該抗体希釈液の適量(たとえば0.5〜1.5
−)ff:容器に入れ、たとえば0〜37℃にて1〜2
4時間静置後希釈液全除去する。洗浄液の過員(たとえ
ば、1〜2m1)を用いて好ましくは1〜3回洗浄する
。洗浄液としては蒸留水、生理穴塩液、これらに0.0
1〜0.1%アルブミンやTween −20を添加溶
解した溶液が使用できる。洗浄後容器を乾燥すれば、抗
ヒ)SP+抗体同定各器容器られる。而して、このよう
にして得られた抗体固定容器に放射性物質標識SP!。
Antibodies, for example, 100 times, 400 times, 1600 times, 6
400x, 25600x, 102400x, 40960x
Dilute to approximately 0 times. Here, the buffer solution is acetate,
Phosphate, tris-hydrochloride etc. are available, especially O
, OIM Sodium Acetate Relaxation Buffer i45.5 is preferred. An appropriate amount of the antibody dilution solution (for example, 0.5 to 1.5
-) ff: Put in a container, for example, 1 to 2 at 0 to 37°C
After allowing it to stand for 4 hours, completely remove the diluent. Washing is preferably carried out 1 to 3 times using excess volumes (for example 1 to 2 ml) of washing liquid. Cleaning liquids include distilled water, physiological saline, and 0.0
A solution containing 1 to 0.1% albumin or Tween-20 can be used. After washing and drying the container, each container for anti-Human SP+ antibody identification can be prepared. Then, the antibody immobilized container obtained in this way was labeled with a radioactive substance SP! .

たとえは+25i標at SP +の約10000 c
pm を加えて緩衝液(たとえばp)16.5〜8.5
)にて金量を好ましくはl−として、たとえば0〜87
°Cにて2〜24時間静置する。静置後、上記と同様の
手段にて洗浄を行って放射活性を測定する。かくして、
用いた放射性物質標識SP、の約40〜60%が結合す
る抗体固定容器金、本発明のキット用として用いること
か好ましい。
For example, +25i mark at SP + about 10000c
Add pm buffer (e.g. p) 16.5 to 8.5
), the gold amount is preferably l-, for example 0 to 87
Let stand at °C for 2 to 24 hours. After standing, the sample is washed using the same method as above, and radioactivity is measured. Thus,
It is preferable to use a gold antibody-immobilized container to which about 40 to 60% of the used radioactive substance labeled SP binds for the kit of the present invention.

不発りjキット用として眞用される緩衝液は、抗原−抗
体反応用のもので、特にpHか6〜9、塩濃度か0.O
1〜0.2M程度のものが好ましい。具体的には、たと
えは0.1MIJン酸塩緩衝化生理食塩液、pH7のも
のがあけられる。
The buffer solution truly used for the Misfire J kit is for antigen-antibody reactions, with a pH of 6 to 9 and a salt concentration of 0. O
A thickness of about 1 to 0.2M is preferable. Specifically, for example, a 0.1 MIJ salt buffered physiological saline solution, pH 7, is used.

本発明キットを使用するヒ)SP、の画定方法は次の通
りである。
The method for defining SP using the kit of the present invention is as follows.

抗ヒ)SP、抗体固定容器に放射性物質標識ヒトSP1
の緩衝液溶液及び被検液(被検尿)を加えてインキュベ
ーションする。かくして固定抗体と放射性物質標識ヒト
sp、及び被検液中のSPlとが抗原−抗体反応によっ
て結合体(8体)を形成する。
Anti-Human SP1, radioactively labeled human SP1 in antibody immobilized container
A buffer solution and a test solution (test urine) are added and incubated. In this way, the immobilized antibody, the radioactive substance-labeled human sp, and the SP1 in the test solution form conjugates (8 bodies) through an antigen-antibody reaction.

ところで、本発明においては抗ヒ)SP、抗体は容器に
固定されているので遊離の放射性物質標識SF1及び被
検液中の遊離のSP、(即ちこれらはF体に相当する)
は、容器中の故を除去することによって容易に除去でき
る。即ち、不発り」においてij B / F分PIP
、か極めて容易である。
By the way, in the present invention, since the anti-Human SP and antibody are immobilized on the container, the free radioactive substance-labeled SF1 and the free SP in the test solution (that is, these correspond to the F form)
can be easily removed by removing the waste in the container. i.e. ij B/F min PIP in "misfire"
, is extremely easy.

B/F分離を行った後容器の放射活性を測定する。この
とき被検液中のSP、量か多ければ多い程放射性物f1
標識ヒト尿SP1の結合槓が少なくなるので放射活性値
は小さくなる。
After performing B/F separation, the radioactivity of the container is measured. At this time, the SP in the test solution, the larger the amount, the more radioactive substance f1
Since less labeled human urine SP1 binds, the radioactivity value becomes smaller.

一方、」二記被検赦の代りに標準ヒ)SP、の種々濃度
における標準検量線を作成し、これと扱検イ函の放射活
性値を対比して被検液中のSP Iを疋(財)する。
On the other hand, standard calibration curves were prepared at various concentrations of the standard H)SP instead of the two test samples, and the SP I in the test solution was determined by comparing this with the radioactivity value of the test box. (goods) to do.

標牟倹州、線は、次の如くして作成されろ。Create the line as follows.

Logit−1og paperの縦軸にNX1(10
(ただし、BOは放射性物質標識ヒhsP、のみを最大
量抗ヒトsp、抗体固定容器に結合さセた時の放射活性
値、Bは各希釈度における標準ヒ)SP、及び放射性物
質標識ヒトSl’、を結合させた時の放射活性値)を、
横軸にヒトSP Hiti (n W/”48:: l
 kとり、標準ヒトSP+の各濃度における姐を結ぶこ
とにより゛C作成される。
NX1 (10
(However, BO is the radioactivity value when bound to the maximum amount of anti-human sp, antibody-immobilized container, and standard hsP at each dilution) SP, and radioactive substance-labeled human Sl ', the radioactivity value when combined,
The horizontal axis shows human SP Hiti (n W/”48:: l
By taking k and connecting the two at each concentration of standard human SP+, 'C' is created.

しかして、各被検液の−5X 100値を氷めハは当該
標準検量縁に合して被検液中に含まれるヒトSP、量(
n2/容(ホ))が測定できる。
Therefore, the -5X100 value of each test solution should be adjusted to match the standard calibration edge, and the human SP contained in the test solution, the amount (
n2/volume (e)) can be measured.

実施例1 (抗ヒトsP、抗体固定化試験管の作成)ヒ)SP、に
対するウサギ抗血溝から硫酸アンモニウム沈澱法および
DEAE−celluloseクロマトグラフィーにて
抗ヒトsPI抗体を精製したのち、001M酢酸ナトリ
ウム、p H5,5を用いて6400倍に希釈した。こ
の希釈液の1meをポリスチレン製試験管(1,Ox 
7.5ヒMりに入れ、87°Cにて4時間静置した。試
験管内液を吸引除去したのち、0.05%の牛血清アル
グミ/を含有″j乙生理食塩液の1,5−を用いて2回
洗浄した。さらに0.01%NaN3含有の生坤食塩液
の1.5mgで1回洗浄した。
Example 1 (Preparation of anti-human sP, antibody-immobilized test tube) Anti-human sPI antibody was purified from rabbit anti-blood grooves against SP by ammonium sulfate precipitation method and DEAE-cellulose chromatography, and then purified with 001M sodium acetate, It was diluted 6400 times using pH 5.5. 1me of this diluted solution was added to a polystyrene test tube (1, Ox
The mixture was placed in a 7.5 ml of water and allowed to stand at 87°C for 4 hours. After removing the solution in the test tube by suction, it was washed twice with 1,5- of physiological saline containing 0.05% bovine serum alguminum. Washed once with 1.5 mg of the solution.

25℃にて送風乾燥した。It was dried by blowing air at 25°C.

参考例1 (本キットによるSP、の測定) 抗ヒ)SP、抗体固定猷靜管紀リン酸塩緩衝化生理大地
液tD 0.8 rnt、+257−標識SP、溶液0
. l rtt(約110000cp含有)、及び被検
体の0.1 +d t■え、攪拌後、37“Cにて4時
間静置した。試除犠′内敢を吸引1余去後、蒸悄水の1
.、5 meを用いて2回洗浄したのち、カンマ−カウ
ンターにより放射活性を氾]j定した。一方、」二記反
応液中、被検体のかわりに標#−8PI溶敵のO,Lm
ll (SPlとしては、1nf’、4n?、16nf
、64n5i’、128ny 含有)を用いた反応糸に
より標準検量線を作成した。伏検体で反応させたあ、除
骨の放射活性ケ検量線と比較することにより、破イリヱ
址に含まれるヒトSP、の量を求めた。
Reference Example 1 (Measurement of SP using this kit) Anti-Human SP, antibody-immobilized phosphate-buffered physiological earth solution tD 0.8 rnt, +257-labeled SP, solution 0
.. 1 rtt (containing about 110,000 cp) and 0.1 + d t of the specimen, stirred, and allowed to stand at 37°C for 4 hours. 1
.. After washing twice with ., 5me, radioactivity was determined using a comma counter. On the other hand, in the reaction solution described above, instead of the analyte, O, Lm of the standard #-8PI dissolved
ll (as SPl, 1nf', 4n?, 16nf
, 64n5i', 128ny) was used to prepare a standard calibration curve. The amount of human SP contained in the broken bones was determined by comparing the reaction with the radioactivity calibration curve of the removed bones.

参考例2 ヒト胎盤抽出液400j[ヒト胎盤(平均重量600g
/個)、約420個のミンチを生理共塩液で懸濁したも
の]を、IN−H(lでpH4,8に調整し、3〜4日
間m・直させンt、後、不要、なムコイド画幻、ヘム画
分を遠心分離(3000rpmX15りJ)で除去し7
ヒ。その上鍔に硫安金側えて(p 147.0で)5条
飽和にし、生じる沈波會遠心分IWI:で分^1「除去
し、得られた上を膚に丈に硫安を加えることにより硫安
飽和60藁とした。得らハた沈減を0.02Mリン酸緩
衝液CpH6,8)K溶解し、同緩衝液で透析したのち
、その透析内液をセファデックスG −150(ファル
マシア社製)カラムにアゲライし、分子量マーカーを用
いて、分子量8〜12万ダルトンの両分を分収した。丈
に、この両分を非妊娠性正常ヒト血漿抗体(ウッ°ギ)
−セファロースのカラムにアプライして、 SP、を溶
Wさせた。得られた未吸着画分を硫安40%飽和により
a細し、次いで同上の緩衝液で透析した後、凍結乾燥゛
し乾燥粉末のSP、 B Q fを得た。このSP、は
、要すれば更に高速液体クロマトグラフィーまたは20
マド77j’−j)’/ングのような電気泳動法により
て高に精製さhmJ物への免疫用抗原とすることができ
る。
Reference Example 2 Human placenta extract 400j [Human placenta (average weight 600g)
420 pieces of minced meat suspended in physiological saline solution] was mixed with IN-H (adjusted to pH 4.8 with l, left to cure for 3 to 4 days, then unneeded, The mucoid fraction and heme fraction were removed by centrifugation (3000 rpm
Hi. Furthermore, by attaching the ammonium sulfate side to the brim (at p 147.0) and saturating it with 5 strips, the resulting sedimentation centrifugation fraction IWI: was removed by 1 minute, and the obtained upper layer was added to the skin by adding ammonium sulfate to a length. The resulting sediment was dissolved in 0.02 M phosphate buffer (CpH 6,8) K and dialyzed against the same buffer. Using a molecular weight marker, we separated both fractions with a molecular weight of 80,000 to 120,000 Daltons.
- It was applied to a Sepharose column to dissolve SP. The resulting unadsorbed fraction was atomized by 40% saturation with ammonium sulfate, then dialyzed against the same buffer solution, and then lyophilized to obtain dry powders of SP and BQf. This SP, if necessary, can be further processed by high performance liquid chromatography or
It can be highly purified by an electrophoretic method such as MAD77j'-j)'/ng and used as an antigen for immunization against hmJ.

文献 1) Greenwood 、F、C,et al、 
+Biochem。
Reference 1) Greenwood, F. C., et al.
+Biochem.

J、、89.114(1968) 2) Miyachi Y、 、et al * J、
 Cl1n。
J, 89.114 (1968) 2) Miyachi Y, et al * J,
Cl1n.

Endocrinol、Metab、 、 84 、2
8 (1972)8) Bolton、 A、h、 、
 and Hunter 、W、M、 。
Endocrinol, Metab, 84, 2
8 (1972) 8) Bolton, A.h.
and Hunter, W.M.

Claims (1)

【特許請求の範囲】[Claims] (1)抗ヒト妊娠特異蛋白抗体固定容器、放射性物質標
識ヒト妊娠特異蛋白及び標準ヒト妊娠特異蛋白及び緩衝
液よりなるヒト妊娠特異蛋白定量用キット。
(1) A human pregnancy-specific protein quantification kit consisting of an anti-human pregnancy-specific protein antibody immobilization container, a radioactive substance-labeled human pregnancy-specific protein, a standard human pregnancy-specific protein, and a buffer solution.
JP8947783A 1983-05-20 1983-05-20 Kit for measuring specific protein in human pregnancy Pending JPS59214767A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8947783A JPS59214767A (en) 1983-05-20 1983-05-20 Kit for measuring specific protein in human pregnancy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8947783A JPS59214767A (en) 1983-05-20 1983-05-20 Kit for measuring specific protein in human pregnancy

Publications (1)

Publication Number Publication Date
JPS59214767A true JPS59214767A (en) 1984-12-04

Family

ID=13971808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8947783A Pending JPS59214767A (en) 1983-05-20 1983-05-20 Kit for measuring specific protein in human pregnancy

Country Status (1)

Country Link
JP (1) JPS59214767A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2628743A1 (en) * 1988-03-18 1989-09-22 Agronomique Inst Nat Rech NOVEL GESTATION RECOGNITION PROTEIN IN MAMMALS, APPLICATIONS FOR EARLY DETECTION OF GESTATION AND PROCESS FOR PREPARING SAID PROTEIN
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2628743A1 (en) * 1988-03-18 1989-09-22 Agronomique Inst Nat Rech NOVEL GESTATION RECOGNITION PROTEIN IN MAMMALS, APPLICATIONS FOR EARLY DETECTION OF GESTATION AND PROCESS FOR PREPARING SAID PROTEIN
GR890100161A (en) * 1988-03-18 1990-01-19 Agronomique Inst Nat Rech Novel antigen associated with early detection of mammalian pregnacy
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications

Similar Documents

Publication Publication Date Title
Chavers et al. A solid phase fluorescent immunoassay for the measurement of human urinary albumin
US6114180A (en) Synthetic calibrators for use in immunoassays, comprising the analytes or partial sequences thereof which are conjugated to inert carrier molecules
JPS60501179A (en) Detection method and detection article for human T-cell leukemia virus
IE44471B1 (en) Stable preparation of erythrocytes process for preparing it and its use
JPS60259964A (en) Assay of immunologically active substance in analysis sample
US5925533A (en) Tropinin I calibrator and method of use thereof in a sandwich immunoassay
NL8102178A (en) METHOD FOR DEMONSTRATING ANTI-ANTIGENS AGAINST CERTAIN ANTIGENS, EQUIPMENT AND REAGENTS FOR CARRYING OUT THIS METHOD
JP2558442B2 (en) L1 protein
EP0108992B1 (en) Immunoassay
EP0283779B1 (en) Method of assaying high molecular hyaluronic acid
US3562384A (en) Immunological indicator and test system
FI60319C (en) FOERFARANDE FOER PAOVISNING ELLER BESTAEMNING AV ANTIKROPPAR I KROPPSVAETSKOR MED HJAELP AV KAENDA ANTIGENER ELLER FOER BESTTAEMNING AV ANTIGENER MED HJAELP AV KAENDA ANTIKROPPAR FRAON KROPPSVAETSKOR SAMT MED
JPH08512138A (en) Random detection of antigen by antibodies immobilized on soluble submicron particles
JPH10160734A (en) Mixture for calibration/control for immunoassay
EP0095286B1 (en) Immunoassay
EP0122620B1 (en) Reagent and kit for determination of blood coagulation factor xiii
JPS63150669A (en) Method of measuring hyaluronic acid
JPS59214767A (en) Kit for measuring specific protein in human pregnancy
NO164135B (en) IMMUNOMETRIC METHOD FOR DETERMINING A HAPTEN, AND ANALYTICAL METHOD FOR PERFORMING THE METHOD.
Rush et al. Solid-phase radioimmunoassay on polystyrene beads and its application to dopamine-β-hydroxylase
JPS604423B2 (en) Method for quantifying peptide hormones
JPS60138463A (en) Heterogeneous immunity measuring method using luciferase
JPS5960260A (en) Enzyme immunological measurement
JPS58221166A (en) Carrier for immunochemical measurement and measuring reagent using this carrier
JPS6329248A (en) Diagnostic immunity testing method by solid phase separation